

**Beyond relief:**

**biomarkers of the anti-inflammatory effect and  
dose selection of COX inhibitors in early drug  
development**

## **Cover design Fire I by Jennifer Shifflet**

**Artist statement:** “The painting is a part of a series of internal landscapes that were inspired by MRIs of my body. It is an exploration of the process of visually bringing light, harmony, and color into areas of my body, particularly the spine, that suffers from chronic pain and imbalance. Elements of the natural world, such as fire, are used as metaphors for the experience of embodiment. Painting is a means for me to transform and find meaning in, what cannot otherwise be healed through conventional medicine. By moving towards and within the experience of pain itself, they attempt to both express sensation and transform suffering.”

Cover art courtesy of [PainExhibit.com](http://PainExhibit.com).

**Beyond relief:  
biomarkers of the anti-inflammatory effect and dose selection of  
COX inhibitors in early drug development**

**Proefschrift**

ter verkrijging van  
de graad van Doctor aan de Universiteit Leiden,  
op gezag van Rector Magnificus prof.mr. P.F. van der Heijden,  
volgens besluit van het College voor Promoties  
te verdedigen op dinsdag 18 november 2008  
klokke 11:15 uur

door

**Dymphy Regien Hans Huntjens**

geboren te Maastricht

in 1979

## Promotiecommissie

Promotor: Prof. Dr. M. Danhof

Co-promotor: Dr. O. E. Della Pasqua

Referent: Prof. Dr. C. Patrono  
(Catholic University School of Medicine, Rome, Italy)

Overige leden:  
Prof. Dr. A.F. Cohen  
Prof. Dr. T. Hankemeier  
Prof. Dr. E. R. De Kloet  
Prof. Dr. A. P. IJzerman  
Prof. Dr. H. J. Guchelaar

The research described in this thesis was sponsored by GlaxoSmithKline and conducted at the Division of Pharmacology of the Leiden/Amsterdam Center for Drug Research, Leiden University, The Netherlands and the Department of Drug Metabolism and Pharmacokinetics of GlaxoSmithKline in Harlow, United Kingdom.

**"Knowing is not enough; we must apply.  
Willing is not enough; we must do it."**

*Johann Wolfgang von Goethe*  
1749-1832

Aan Kasper  
Voor Lars

The printing of this thesis was financially supported by:

Harlan Netherlands B.V., Horst, The Netherlands

Johnson & Johnson, Pharmaceutical Research and development, Beerse, Belgium

Leiden/Amsterdam Center for Drug Research, Leiden, The Netherlands

Mango Solutions, Chippenham, UK

ISBN 978-90-8570-313-6

©2008 Dymphy Huntjens

No part of this thesis may be reproduced or transmitted in any form or by any means without written permission from the author.

## Table of Contents

### Section I General introduction

Chapter 1	General Introduction: Inflammation, pain and analgesic drug effects	11
Chapter 2	PKPD correlations and biomarkers in the development of COX-2 inhibitors	29
Chapter 3	Scope and intent of investigation	57

### Section II PKPD modelling of biomarkers

Chapter 4	Correlation between <i>in vitro</i> and <i>in vivo</i> concentration–effect relationships of naproxen in rats and healthy volunteers	65
Chapter 5	Population pharmacokinetic modelling of the enterohepatic recirculation of diclofenac and rofecoxib in rats	85
Chapter 6	Differences in the <i>in vitro</i> and <i>in vivo</i> concentration–effect relationship of selective and non-selective COX inhibitors: role of translational pharmacology in pain research	109
Chapter 7	Impact of chronic inflammation on the pharmacokinetic–pharmacodynamic relationships of naproxen	133

### Section III PKPD modelling of analgesia

Chapter 8	Differences in the sensitivity of behavioural measures of pain to the selectivity of cyclo-oxygenase inhibitors	153
Chapter 9	Unravelling the relationship between exposure, biomarker and analgesic response to COX inhibitors in chronic inflammatory pain	173

### Section IV Clinical extrapolation and inter-species scaling

Chapter 10	Model-based prediction of the effect of COX inhibitors and optimal dosing in patients with systemic lupus erythematosus	195
------------	---	-----

### Section V Conclusions and perspectives

Chapter 11	Biomarkers of the anti-inflammatory effect and dose selection of COX inhibitors in early drug development: summary, conclusions and perspectives	221
Chapter 12	Nederlandse samenvatting	241
	List of publications	249
	Curriculum Vitae	251
	Nawoord	253

